Xenetic Biosciences Announces Oral Presentation at 68th ASH Annual Meeting Highlighting DNase I as a Potential Strategy to Overcome CAR T-Cell Resistance
Key Highlights
- ➤Xenetic (XBIO) research selected for oral presentation at 68th ASH Annual Meeting
- ➤DNase I may reverse CAR T-cell resistance driven by extracellular chromatin
- ➤Presentation examines a self-reinforcing resistance niche formed during CAR T-cell killing
- ➤Systemic DNase program targets pancreatic carcinoma and advanced or metastatic solid tumors
Expert Statements
Alexey Stepanov, Institute Investigator, Department of Integrative Structural and Computational Biology, Scripps Research
“Extracellular chromatin released during CAR T-cell killing establishes a self-reinforcing resistance niche reversed by DNase I”
FRAMINGHAM, MA / ACCESS Newswire / November 4, 2026 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that the Company's research examining a mechanism of resistance to CAR T-cell therapy and the potential of DNase I to reverse this process has been selected for oral presentation at the 68th American Society of Hematology (ASH) Annual Meeting. The conference will take place December 12-15, 2026, in New Orleans, Louisiana, and virtually.
The presentation will examine how extracellular chromatin released during CAR T-cell killing establishes a self-reinforcing resistance niche and how DNase I reverses this process. By investigating a resistance mechanism that arises during CAR T-cell killing itself, the research addresses a central challenge in the field: understanding how the response to tumor-cell destruction may create conditions that limit continued treatment activity.
Get started
Create a free account to read the full story.